On predicting the response to antidepressant treatment

Human Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 343-344

  Baldwin, David S ^a,b   Bolognesi, Francesca ^a,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHERN HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C19; ESCITALOPRAM; PHARMACOLOGICAL BIOMARKER; SEROTONIN TRANSPORTER; VENLAFAXINE;

ACCURACY; ANXIETY DISORDER; CLINICAL ASSESSMENT; DEPRESSION; DISEASE SEVERITY; DNA POLYMORPHISM; EDITORIAL; GENOTYPE; HUMAN; NEUROIMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER; HUMANS; INDIVIDUALIZED MEDICINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84864153785     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2232     Document Type: Editorial

References (14)

1. Baldwin DS,. 2011. Where is the room for improvement in the drug treatment of depression and anxiety? Hum Psychopharmacol Clin Exp 26: 1-3.
2. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B,. 2009. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol Clin Exp 24: 269-275.
3. Dawson GR, Dourish CT, Goodwin GM,. 2011. Special issue on CNS experimental medicine. J Psychopharmacol 25: 1145-1147.
4. Domschke K, Dannlowski U, Hohoff C, et al,. 2010. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 20: 301-309.
5. Fava M, Rush AJ, Alpert JE, et al,. 2008. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 165: 342-351.
6. Harmer CJ, Cowen PJ, Goodwin GM,. 2011. Efficacy markers in depression. J Psychopharmacol 25: 1148-1158.
7. Hou R, Baldwin DS,. 2012. A neuroimmunological perspective on anxiety disorders. Hum Psychopharmacol Clin Exp 27: 6-14.
8. Huezo-Diaz P, Perroud N, Spencer P, et al,. 2012. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 26: 398-407.
9. Keers R, Bonvicini C, Scassellati C, et al,. 2011. Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol 25: 867-874.
10. Kennedy SH, Andersen HF, Thase ME,. 2009. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 25: 161-175.
11. Papakostas GI,. 2011. Surrogate markers of treatment outcome in major depressive disorder. Int J Neuropsychopharmacol Aug 4: 1-14 (E-pub ahead of print).
12. Porcelli S, Fabbri C, Serretti A,. 2012. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22: 239-258.
13. Schmitt AB, Bauer M, Volz HP, et al,. 2009. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur Arch Psychiatry Clin Neurosci 259: 329-339.
14. Serretti A, Olgiat P, Bajo E, Bigelli M, De Ronchi D,. 2011. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 12: 501-515.